Publications for Jan-Edvin Olsson
Co-author map based on ISI articles 2007-

Publications mentioned in social media 1 times*

Keywords

trial treatment tinzaparin taist subtype stroke snss severity pd patients median l-dopa ischaemic functional disease death clinical blood baseline adjusted

Journal Articles

N. Sprigg, L.J. Gray, P.M.W. Bath, E. Lindenstrom, G. Boysen, Deyn P.P. De, P. Friis, D. Leys, R. Marttila, Jan-Edvin Olsson, D. O'Neill, E.B. Ringelstein, der Sande J.-J. van and A.G.G. Turpie
  Early Recovery and Functional Outcome are Related with Causal Stroke Subtype: Data from the Tinzaparin in Acute Ischemic Stroke Trial
 
Altmetric usage: 1

  Journal of Stroke & Cerebrovascular Diseases, 2007, 16(4), 180-184.

N. Sprigg, L.J. Gray, P.M.W. Bath, E. Lindenstrom, G. Boysen, Deyn P.P. De, P. Friis, D. Leys, R. Marttila, Jan-Edvin Olsson, D. O'Neill, E.B. Ringelstein, der Sande J.-J. van and A.G.G. Turpie
  Stroke severity, early recovery and outcome are each related with clinical classification of stroke: Data from the 'Tinzaparin in Acute Ischaemic Stroke Trial' (TAIST)
  Journal of the Neurological Sciences, 2007, 254(1-2), 54-59.
 Web of Science® Times Cited: 11

Nikola Sprigg, Laura J Gray, Philip MS Bath, Ewa Lindenström, Gudrun Boysen, Peter Paul De Deyn, Pal Friis, Didier Leys, Reijo Marttila, Jan-Edvin Olsson, Desmond ONeil, Erich Bernd Ringelstein, Jan-Jacob van der Sande and Alexander GG Turpie
  Early recovery and functional outcome are related with causal stroke subtype: Data from the tinzaparin in acute ischemic stroke trial.
  Journal of Stroke & Cerebrovascular Diseases, 2007, 16(4), 180-184.

Nikola Sprigg, Laura J Gray, Philip M W Bath, Gudrun Boysen, Peter Paul De Deyn, Pal Friis, Didier Leys, Reijo Marttila, Jan-Edvin Olsson, Desmond O´Neill, Bernd Ringelstein, Jan- Jacob van der Sande and Ewa Lindenström
  elationship between outcome and baseline blood pressure and other haemodynamic measures in acute ischaemic stroke: Data from the TAIST trial
  Journal of Hypertension, 2006, 24(7), 1413-1417.
 Web of Science® Times Cited: 36

Karl Ekbom, Lena Leissner, Jan-Edvin Olsson and Håkan Widner
  Restless legs - vanligt sjukdomstillstånd som ofta missas. Möjligheter till framgångsrik behandling finns idag
  Läkartidningen, 2006, 103, 207-211.

L J Gray, N Sprigg, P M W Bath, P Sörensen, E Lindenström, G Boysen, P P De Deyn, P Friis, D Leys, R Marttila, Jan-Edvin Olsson, D O´Neill, B Ringelstein, J-J van der Sande and A G G Turpie
  Significant variation in mortality and functional outcome after acute ischaemic stroke between western countries: Data from the tinzaparin in acute ischaemic stroke trial (TAIST)
  Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77(3), 327-333.
 Web of Science® Times Cited: 17

Dominic C Paviour, Tamas Revesz, Janice L Holton, Andrew Evans, Jan-Edvin Olsson and Andrew J Lees
  Neuronal intranuclear inclusion disease: Report on a case originally diagnosed as dopa-responsive dystonia with lewy bodies
  Movement Disorders, 2005, 20(10), 1345-1349.
 Web of Science® Times Cited: 8

Veronica Murray, Magnus von Arbin, Aniko Bartfai, Anna-Lena Berggren, Anne-Marie Landtblom, Jöns Lundmark, Per Näsman, Jan-Edvin Olsson, Margareta Samuelsson, Andreas Terént, Riitta Varelius, Marie Åsberg and Björn Mårtensson
  Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression
  Journal of Clinical Psychiatry, 2005, 66(6), 708-716.
 Web of Science® Times Cited: 46

Jan-Edvin Olsson
  Ny MAO-hämmare vid behandling av Parkinsons sjukdom
  Transmittorn, 2005, 1, .

Jan-Edvin Olsson
  Några reflektioner från American Academy of Neurology, 55th Annual Meeting, 2003, Honolulu, Hawaii
  Parkinson-journalen, 2003, 4, 22-23.

Per-Arne Fall, Avin Saleh, Mats Fredrikson, Jan-Edvin Olsson and Ann-Kathrine Granerus
  Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: A 9-year follow-up
  Movement Disorders, 2003, 18(11), 1312-1316.
 Web of Science® Times Cited: 72

Jan-Edvin Olsson
  Lipidsänkning och cerebrovaskulär sjukdom - nytta och risker?
  Läkartidningen, 2002, 99, 1967-1969.

Sven-Erik Eriksson and Jan-Edvin Olsson
  Survival and recurrent strokes in patients with different subtypes of stroke: A fourteen-year follow-up study
  Cerebrovascular Diseases, 2001, 12(3), 171-180.
 Web of Science® Times Cited: 65

Philip M W Bath, Ewa Lindenstrom, Gudrom Boysen, Peter De Deyn, Pal Friis, Didier Leys, Reijo Marttila, Jan-Edvin Olsson, Desmond O´Neill, Jean-Marc Orgagozo, Bernd Ringelstein, Jan-Jacob van der Sande and Alexander G G Turpie
  Tinzaparin in acute ischaemic stroke (TAIST): A randomised aspirin-controlled trial
  The Lancet, 2001, 358(9283), 702-710.
 Web of Science® Times Cited: 168

Nil Dizdar (Segrell), Anita Kullman, Björn Norlander, Jan-Edvin Olsson and Bertil Kågedal
  Human pharmacokinetics of L-3,4-dihydroxyphenylalanine studied with microdialysis
  Clinical Chemistry, 1999, 45(10), 1813-1820.

Nil Dizdar (Segrell), Ann-Kathrine Granerus, Ulf Hannestad, Anita Kullman, Å. Ljungdahl, Jan-Edvin Olsson and Bertil Kågedal
  L-dopa pharmacokinetics studied with microdialysis in patients with Parkinson's disease and a history of malignant melanoma
  Acta neurologica Scandinavica, 1999, 100(4), 231-237.

Per-Arne Fall, Olav Axelson, Mats Fredrikson, Gunilla Hansson, Björn Lindvall, Jan-Edvin Olsson and Ann-Kathrine. Granérus
  Age standardised incidence and prevalence of Parkinson´s disease in a Swedish community
  Journal of Clinical Epidemiology, 1996, 49(6), 637-641.

Conference Articles

Jan-Edvin Olsson, J Ohrvik and S Palhagen
  "The Swedish Parkinson Kohort Study" : an Interim Analysis after 7 years
  XVIII World Congress of Neurology,2005, 2005.


V Murray, M Von Arbin, R Varelius, Jan-Edvin Olsson, A Terent, M Samuelsson, AL Berggren, Anne-Marie Landtblom, M Asberg, A Bartfai, F Bengtsson and B Martensson
  Sertraline in poststroke depression - A controlled study
  Stroke, 2002.


 Web of Science® Times Cited: 1

Ph.D. Theses

Nil Dizdar (Segrell)
  Microdialysis as a Tool in Studies of L-Dopa and Metabolites in Malignant Melanoma and Parkinson’s Disease
  1999.


  Fulltext PDF

* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.